profit from every $100 of sales.
$0$100
SIGA Technologies
$2.74-5.19% today
-54.9% in 1 year
1-year low $2.741-year high $6.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $8.46 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What SIGA Technologies sold, what it kept, and what it did with the cash.
Sales went from $111 million in 2022 to $94.6 million in 2025, with $23.3 million of profit last year.
SalesProfit
SIGA Technologies handed back more cash to shareholders than it generated last year.
$43M
Free cash flow 2025$43M
Bought back its own shares$0
Paid as dividends$43M
Cash vs. debt$155M vs. $595,169
SIGA Technologies vs. similar companies
SIGA Technologies grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SIGA Technologies | 8.5× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads SIGA Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 111 | 140 | 139 | 95 | |
| 100 | 122 | 107 | 65 | |
| 43 | 84 | 70 | 24 | |
| 43 | 84 | 71 | 24 | |
| 34 | 68 | 59 | 23 | |
| 0.46 | 0.95 | 0.82 | 0.32 | |
| 90.6% | 87.3% | 77.4% | 68.6% | |
| 38.5% | 59.8% | 50.4% | 25.1% | |
| 30.6% | 48.6% | 42.7% | 24.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 195 | 254 | 244 | 219 |
| Cash | 99 | 150 | 155 | 155 |
| Total debt | 1 | 1 | 1 | 1 |
| Total liabilities | 25 | 57 | 29 | 21 |
| 170 | 197 | 216 | 199 | |
| 74 | 72 | 72 | 72 | |
| 19.8% | 33.5% | 25.6% | 9.4% | |
| 19.9% | 34.6% | 27.4% | 11.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 42 | 95 | 49 | 43 | |
| – | 0 | 0 | 0 | |
| 42 | 95 | 49 | 43 | |
| Dividends paid | 33 | 32 | 43 | 43 |
| 13 | 11 | 0 | 0 | |
| 2 | 2 | 4 | 4 |
Valuation
- 8.5×
- 1.6×
- –
- 2.2×
- 2.1×
- 4.6×
- 1.8×
- 21.9%
- 11.8%
- 12.8%
Profitability
- 68.6%
- 25.1%
- 24.6%
- 26.2%
- 10.0%
- 26.6%
- 10.6%
- 9.2%
- 13.4%
- 2,884,018.5%
Growth
- −5.1%
- −11.4%
- −11.5%
- –
- −1.3%
Financial health
- -5.9×
- 0.00
- 0.3%
- –
- 3.25
- 2.38
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 31%of 963
Top 15%of 894
Top 7%of 632
Bottom 10%of 908
Top 2%of 991
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.05 | – | – |
| Mar 10, 2026 | -0.08 | – | – |
| Nov 6, 2025 | -0.09 | – | – |
| Aug 5, 2025 | 0.49 | – | – |
| May 8, 2025 | -0.01 | – | – |
| Mar 11, 2025 | 0.63 | – | – |
| Nov 7, 2024 | 0.02 | – | – |
| Aug 1, 2024 | 0.03 | – | – |
12.8%of the share price, paid each year
On $1,000 invested$128a year at today's yield, before tax
–per share
Raised–not every year
Paid per share, each year
$0.45 in 2022 → $0.60 in 2025
How safe it looks
185.2% of its profit
Room to growStretchedMore than it earns: 100.0%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
82Pass
Benjamin Graham
86Pass
Philip Fisher
71Pass
Peter Lynch
35No pass
Joel Greenblatt
64Pass
Charlie Munger
85Pass
Terry Smith
79Pass
Questions about SIGA Technologies
Is SIGA Technologies a good stock to buy?
A strong, very profitable business, and the price looks low. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SIGA Technologies AI analysis
What does SIGA Technologies do?
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. It is in Drug Manufacturers - Specialty & Generic.
Does SIGA Technologies pay a dividend?
Yes. At today's price the dividend is 12.8% a year, about 185% of its yearly profit. In 2025 it paid out $43.1 million in dividends.
Is SIGA Technologies stock halal?
No. SIGA Technologies does not pass our halal screen: its cash and confirmed interest-bearing investments are 79% of its market value, at or above the 33% limit. How we check
How has SIGA Technologies stock done over the past year?
Down 54.9% over the past twelve months, to $2.74. It traded between $2.74 and $6.95 and is 60.6% below its high.
Who are SIGA Technologies's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with SIGA Technologies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.